Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989;28(Suppl 1):15S–22S.

Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure

S J S Virk, M K Davies
PMCID: PMC1379872  PMID: 2572250

Abstract

1 A bicycle exercise test was used to investigate functional capability and haemodynamics in 30 patients with heart failure (13 NYHA Class II, 17 Class III), before and after i.v. xamoterol (Corwin, Carwin, Corwil, Xamtol, ICI 118,587) 0.2 mg kg-1.

2 Resting heart rate fell from 78 to 74 beats min-1 (P < 0.05) and cardiac index rose from 2.5 to 2.8 l min-1 m-2 (P < 0.001) after xamoterol. Blood pressure fell slightly, and systemic vascular resistance was reduced. Stroke work index improved and double produced decreased. There were no changes in pulmonary artery wedge pressure, ejection fraction or plasma noradrenaline concentrations.

3 On exercise, xamoterol produced a considerable reduction in heart rate increase, improved stroke volume and left ventricular stroke index and lowered double product. Exercise duration increased by 10%, but this did not quite achieve statistical significance.

4 These results are consistent with the concept that a β1-partial adrenoceptor agonist with the level of intrinsic sympathomimetic activity (43%) of xamoterol provides moderate inotropic support at rest, and protects the heart against overstimulation on exercise, when sympathetic drive is high.

5 Reduction of double product on exercise implies a lowered oxygen demand, which could be of considerable importance in patients with ischaemic heart disease.

Keywords: xamoterol, heart failure, β1-adrenoceptor, partial agonist

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amende I., Simon R., Hood W. P., Jr, Lichtlen P. R. Die akute Wirkung des kardioselektiven beta-1-partiellen Agonisten, Corwin, auf die Ventrikelfunktion und den myokardialen Sauerstoffverbrauch bei Patienten mit dilativer Kardiomyopathie. Z Kardiol. 1986 May;75(5):291–295. [PubMed] [Google Scholar]
  2. Bhatia S. J., Swedberg K., Chatterjee K. Acute hemodynamic and metabolic effects of ICI 118,587 (Corwin), a selective partial beta 1 agonist, in patients with dilated cardiomyopathy. Am Heart J. 1986 Apr;111(4):692–696. doi: 10.1016/0002-8703(86)90101-8. [DOI] [PubMed] [Google Scholar]
  3. Bobik A., Campbell J. H., Carson V., Campbell G. R. Mechanism of isoprenaline-induced refractoriness of the beta-adrenoceptor--adenylate cyclase system in chick embryo cardiac cells. J Cardiovasc Pharmacol. 1981 May-Jun;3(3):541–553. doi: 10.1097/00005344-198105000-00013. [DOI] [PubMed] [Google Scholar]
  4. Bristow M. R., Ginsburg R., Minobe W., Cubicciotti R. S., Sageman W. S., Lurie K., Billingham M. E., Harrison D. C., Stinson E. B. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982 Jul 22;307(4):205–211. doi: 10.1056/NEJM198207223070401. [DOI] [PubMed] [Google Scholar]
  5. CHIDSEY C. A., BRAUNWALD E., MORROW A. G. CATECHOLAMINE EXCRETION AND CARDIAC STORES OF NOREPINEPHRINE IN CONGESTIVE HEART FAILURE. Am J Med. 1965 Sep;39:442–451. doi: 10.1016/0002-9343(65)90211-1. [DOI] [PubMed] [Google Scholar]
  6. Cohn J. N., Levine T. B., Olivari M. T., Garberg V., Lura D., Francis G. S., Simon A. B., Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984 Sep 27;311(13):819–823. doi: 10.1056/NEJM198409273111303. [DOI] [PubMed] [Google Scholar]
  7. Colucci W. S., Alexander R. W., Williams G. H., Rude R. E., Holman B. L., Konstam M. A., Wynne J., Mudge G. H., Jr, Braunwald E. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol. N Engl J Med. 1981 Jul 23;305(4):185–190. doi: 10.1056/NEJM198107233050402. [DOI] [PubMed] [Google Scholar]
  8. Detry J. M., Decoster P. M., Brasseur L. A. Hemodynamic effects of Corwin (ICI 118,587), a new cardioselective beta-adenoceptor partial agonist. Eur Heart J. 1983 Aug;4(8):584–591. doi: 10.1093/oxfordjournals.eurheartj.a061524. [DOI] [PubMed] [Google Scholar]
  9. Detry J. M., Decoster P. M., Buy J. J., Rousseau M. F., Brasseur L. A. Antianginal effects of corwin, a new beta-adrenoceptor partial agonist. Am J Cardiol. 1984 Feb 1;53(4):439–443. doi: 10.1016/0002-9149(84)90009-2. [DOI] [PubMed] [Google Scholar]
  10. Francis G. S., Goldsmith S. R., Cohn J. N. Relationship of exercise capacity to resting left ventricular performance and basal plasma norepinephrine levels in patients with congestive heart failure. Am Heart J. 1982 Oct;104(4 Pt 1):725–731. doi: 10.1016/0002-8703(82)90003-5. [DOI] [PubMed] [Google Scholar]
  11. Ikäheimo M. J., Takkunen J. T. The effects of beta 1-adrenoceptor partial agonist ICI 118.587 on left ventricular function in patients with coronary heart disease. Int J Cardiol. 1984 Mar;5(3):339–349. doi: 10.1016/0167-5273(84)90111-6. [DOI] [PubMed] [Google Scholar]
  12. Levine T. B., Francis G. S., Goldsmith S. R., Simon A. B., Cohn J. N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982 May;49(7):1659–1666. doi: 10.1016/0002-9149(82)90243-0. [DOI] [PubMed] [Google Scholar]
  13. McCaffrey P. M., Riddell J. G., Shanks R. G. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551. J Cardiovasc Pharmacol. 1988 May;11(5):543–551. doi: 10.1097/00005344-198805000-00006. [DOI] [PubMed] [Google Scholar]
  14. Mickey J. V., Tate R., Mullikin D., Lefkowitz R. J. Regulation of adenylate cyclase-coupled beta adrenergic receptor binding sites by beta adrenergic catecholamines in vitro. Mol Pharmacol. 1976 May;12(3):409–419. [PubMed] [Google Scholar]
  15. Molajo A. O., Bennett D. H. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction. Br Heart J. 1985 Jul;54(1):17–21. doi: 10.1136/hrt.54.1.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mukherjee C., Caron M. G., Lefkowitz R. J. Catecholamine-induced subsensitivity of adenylate cyclase associated with loss of beta-adrenergic receptor binding sites. Proc Natl Acad Sci U S A. 1975 May;72(5):1945–1949. doi: 10.1073/pnas.72.5.1945. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rousseau M. F., Pouleur H., Vincent M. F. Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction. Am J Cardiol. 1983 May 1;51(8):1267–1274. doi: 10.1016/0002-9149(83)90297-7. [DOI] [PubMed] [Google Scholar]
  19. Sato H., Inoue M., Matsuyama T., Ozaki H., Shimazu T., Takeda H., Ishida Y., Kamada T. Hemodynamic effects of the beta 1-adrenoceptor partial agonist xamoterol in relation to plasma norepinephrine levels during exercise in patients with left ventricular dysfunction. Circulation. 1987 Jan;75(1):213–220. doi: 10.1161/01.cir.75.1.213. [DOI] [PubMed] [Google Scholar]
  20. Simonsen S. Haemodynamic effects of ICI 118,587 in cardiomyopathy. Br Heart J. 1984 Jun;51(6):654–657. doi: 10.1136/hrt.51.6.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Su Y. F., Harden T. K., Perkins J. P. Catecholamine-specific desensitization of adenylate cyclase. Evidence for a multistep process. J Biol Chem. 1980 Aug 10;255(15):7410–7419. [PubMed] [Google Scholar]
  22. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):134–142. doi: 10.1136/hrt.44.2.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J. 1980 Aug;44(2):117–133. doi: 10.1136/hrt.44.2.117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Thomas J. A., Marks B. H. Plasma norepinephrine in congestive heart failure. Am J Cardiol. 1978 Feb;41(2):233–243. doi: 10.1016/0002-9149(78)90162-5. [DOI] [PubMed] [Google Scholar]
  25. Tse J., Powell J. R., Baste C. A., Priest R. E., Kuo J. F. Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology. 1979 Jul;105(1):246–255. doi: 10.1210/endo-105-1-246. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES